Preoperative (Chemo)Radiotherapy for Locally Recurrent Rectal Cancer
Efficacy and Safety of Preoperative (Chemo)Radiotherapy for Locally Recurrent Rectal Cancer: A Prospective, Single-arm Observational Study
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: YI-KAN CHENG Yi-kan Cheng
- Phone Number: 15102033641
- Email: chengyk3@mail.sysu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510065
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
Contact:
- Yikan Cheng
- Phone Number: 15102033641
- Email: chengyk3@mail.sysu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age between 18 and 75 years
- ECOG performance status of 0-1
- Histologically, cytologically, or MRI/contrast-enhanced CT confirmed pelvic recurrence. At least one measurable pelvic lesion according to RECIST 1.1
- No distant metastases outside the pelvis
- (Potentially) resectable lesion
- No history of radiotherapy within the 6 months prior to enrollment
- No prior chemotherapy; or received postoperative adjuvant therapy but not systemic chemotherapy for metastatic lesions
- Investigator-assessed life expectancy of at least 24 weeks
- Adequate organ function (bone marrow, liver, kidney, and coagulation function) demonstrated within 7 days prior to the first dose, without the use of blood products or hematopoietic growth factors
- Not pregnant or breastfeeding. Effective contraception must be used during the study and for 6 months after the last dose
- Fully informed and willing to provide written informed consent to participate in the trial
Exclusion Criteria:
- Severe electrolyte abnormalities
- Active coronary artery disease, severe/unstable angina, newly diagnosed angina, or myocardial infarction within 12 months prior to study participation Thromboembolic events such as cerebrovascular accidents (including transient ischemic attacks), pulmonary embolism, or deep vein thrombosis within the past 6 months
- New York Heart Association (NYHA) class II or higher congestive heart failure
- Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); untreated active hepatitis (hepatitis B defined as HBV-DNA ≥ 500 IU/ml, or hepatitis C defined as HCV-RNA above the detection limit of the assay) or co-infection with hepatitis B and C
- Active inflammatory bowel disease or other colorectal diseases causing chronic diarrhea
- Any active, known, or suspected autoimmune disease. Stable conditions not required systemic immunosuppressive therapy are allowed, such as type I diabetes, hypothyroidism requiring only hormone replacement therapy, and skin conditions (e.g., vitiligo, psoriasis, and alopecia) not requiring systemic treatment
- Interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic diseases (e.g., diabetes, hypertension, pulmonary fibrosis, or acute pneumonia)
- Known or suspected history of allergy to any study-related medications
- Clinically detectable second primary malignancy or history of another malignancy within the past 5 years
- Pregnant or breastfeeding women, or women with a positive pregnancy test before the first dose, or female participants and their partners unwilling to use strict contraception during the study
- Any clinical or laboratory abnormalities or compliance issues that the investigator deems unsuitable for study participation
- Severe psychiatric disorders
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
pathologic complete response
Time Frame: up to 26 weeks
|
The resected tumor tissue and regional lymph nodes were pathologically assessed, revealing no residual tumor cells.
The tumor lesions had completely disappeared, and no new lesions were detected.
|
up to 26 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
R0 rates
Time Frame: up to 26 weeks
|
The complete tumor resection rate is defined as the absence of cancer cells at the resection margins under a microscope, with no visible or microscopic residual cancer cells, indicating that the lesion has been entirely removed.
|
up to 26 weeks
|
|
progression-free survival
Time Frame: 5 years
|
The interval between the start of enrollment and local recurrence, progression of local recurrence, distant metastasis, or death.
|
5 years
|
|
overall survival
Time Frame: 5 years
|
The interval between the start of enrollment and death.
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2024ZSLYEC-487
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.